Table 1.
Baseline Characteristics of Asymptomatic Patients with Severe AS and LVEF < 50% (n = 43) versus Asymptomatic Patients with Severe AS and LVEF ≥ 50% (n = 122)
| Baseline and Clinical Characteristics |
Asymptomatic, severe AS with LVEF < 50% (n = 43) |
Asymptomatic, Severe AS with LVEF ≥ 50% (n = 122) |
P value |
|---|---|---|---|
| Demographic characteristics | |||
| Age (years, mean ± SD) | 73 ± 14 | 73 ± 13 | 0.941 |
| Male sex (n, %) | 30 (70%) | 86 (70%) | 0.929 |
| Body mass index (kg/m2) | 26.4 ± 3.9 | 27.7 ± 5.4 | 0.241 |
| Assisted living | 2 (4%) | 8 (7%) | 0.644 |
| Historical medical comorbidities | |||
| Systemic hypertension | 33 (78%) | 74 (61%) | 0.05 |
| Smoking history | 20 (47%) | 52 (43%) | 0.659 |
| Atrial fibrillation | 12 (28%) | 20 (16%) | 0.111 |
| Hyperlipidemia | 9 (21%) | 41 (34%) | 0.105 |
| Diabetes mellitus | 5 (12%) | 14 (11%) | 0.979 |
| Cardiac procedures | |||
| Percutaneous coronary intervention | 1 (2%) | 6 (5%) | 0.441 |
| Medical therapy | |||
| Antiplatelet | 16 (37%) | 49 (40%) | 0.733 |
| Diuretic* | 15 (35%) | 40 (33%) | 0.802 |
| Digoxin† | 10 (23%) | 22 (18%) | 0.463 |
| Angiotensin converting enzyme inhibitor or receptor blocker* | 10 (23%) | 24 (20%) | 0.621 |
| Calcium channel blocker* | 9 (21%) | 20 (16%) | 0.508 |
| Beta-blocker* | 7 (16%) | 22 (18%) | 0.709 |
| Coumadin | 6 (14%) | 7 (6%) | 0.103 |
| Statin | 4 (9%) | 21 (17%) | 0.194 |
| Nitrate | 0 (0%) | 5 (4%) | 0.08 |
| Electrocardiographic findings | |||
| LV hypertrophy | 14 (37%) | 29 (24%) | 0.120 |
| Left bundle branch block | 4 (11%) | 2 (2%) | 0.02 |
| Laboratory values | |||
| Hemoglobin (g/dL) | 13 ± 2 | 14 ± 2 | 0.768 |
| Creatinine clearance (mL/min) | 61 ± 28 | 54 ± 10 | 0.288 |
*
For treatment of hypertension.
†
For treatment of atrial fibrillation or flutter.